Longeveron Inc. (LGVN)
Longeveron, Inc. is a clinical stage biotechnology company, which engages in the development of cellular therapies for specific aging-related and life-threatening conditions. Its lead product, LOMECEL-B, is a cell-based therapy product, which is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young, healthy, adult donors. The company was founded by Joshua M. Hare and Donald M. Soffer on October 9, 2014 and is headquartered in Miami, FL.
Address
1951 NW 7TH AVENUE
MIAMI, FL 33136
Founded
2014
Number of Employees
25
Website
http://www.longeveron.com
Buyback
| Buyback Data | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $ Amount Purchased ($ in 000s ) |
- | - | - | - | - | - | - | - | $314 | $149 | $42 | $168 |
| Average Price | - | - | - | - | - | - | - | - | $111.07 | $28.55 | $1.15 | $11.27 |
| # Shares Purchased | - | - | - | - | - | - | - | - | 2,823 | 5,223 | 36,752 | 14,933 |
| Buyback Performance | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Return to Date | - | - | - | - | - | - | - | - | -98.2% | -93.0% | 74.2% | -82.3% |
| S&P 500 Return to Date | - | - | - | - | - | - | - | - | 37.3% | 31.3% | 7.4% | 25.3% |
| Excess Total Return | - | - | - | - | - | - | - | - | -135.5% | -124.3% | 66.8% | -107.6% |
| Quartile Rank |
|
|
|
|
|
|
|
|
|
|
|
|
| Percentile Rank | - | - | - | - | - | - | - | - | 0% | 0% | 98% | 4% |
Buyback returns calculated using weighted average buyback price over the last 10 years and comparing to current day stock price value. S&P 500 used as benchmark for excess return.
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)
People also followed
Never miss an email alert when insiders at LGVN make a trade.
Creating a free account takes less than one minute